Armed with $55M in Third Rock cash, Goldfinch Bio sets out to build a kid­ney dis­ease pipeline

Three years ago, Pe­ter Mundel at Har­vard Med­ical School pub­lished an in­trigu­ing study in the New Eng­land Jour­nal of Med­i­cine that high­light­ed the promise of abat­a­cept in treat­ing a threat­en­ing kid­ney dis­ease. Like many in the field, he was look­ing for ways to adapt ex­ist­ing drugs to fight kid­ney dis­ease.

Now, though, Mundel has shut down his lab at Har­vard and joined a Third Rock start­up that is com­ing out of stealth mode to­day. But in­stead of adapt­ing old drugs for kid­ney dis­ease, the goal is to de­vel­op a pipeline of nov­el ther­a­pies, armed with new in­sights in­to the ge­net­ics of what trig­gers these ail­ments, and how they can be treat­ed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.